CN105985252A - 一种门冬氨酸鸟氨酸晶型iv及其制备方法 - Google Patents
一种门冬氨酸鸟氨酸晶型iv及其制备方法 Download PDFInfo
- Publication number
- CN105985252A CN105985252A CN201510071457.6A CN201510071457A CN105985252A CN 105985252 A CN105985252 A CN 105985252A CN 201510071457 A CN201510071457 A CN 201510071457A CN 105985252 A CN105985252 A CN 105985252A
- Authority
- CN
- China
- Prior art keywords
- aspartic acid
- crystal formation
- acid ornithine
- preparation
- ornithine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- IXUZXIMQZIMPSQ-ZBRNBAAYSA-N [(4s)-4-amino-4-carboxybutyl]azanium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound OC(=O)[C@@H](N)CCC[NH3+].[O-]C(=O)[C@@H](N)CC(O)=O IXUZXIMQZIMPSQ-ZBRNBAAYSA-N 0.000 title abstract description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 70
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 67
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 67
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 67
- 235000003704 aspartic acid Nutrition 0.000 claims description 67
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 67
- 229960003104 ornithine Drugs 0.000 claims description 67
- 230000015572 biosynthetic process Effects 0.000 claims description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 20
- 238000002425 crystallisation Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 230000008025 crystallization Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims description 5
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000002329 infrared spectrum Methods 0.000 claims description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 108010049063 ornithylaspartate Proteins 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510071457.6A CN105985252B (zh) | 2015-02-11 | 2015-02-11 | 一种门冬氨酸鸟氨酸晶型iv及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510071457.6A CN105985252B (zh) | 2015-02-11 | 2015-02-11 | 一种门冬氨酸鸟氨酸晶型iv及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105985252A true CN105985252A (zh) | 2016-10-05 |
CN105985252B CN105985252B (zh) | 2020-02-04 |
Family
ID=57041860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510071457.6A Active CN105985252B (zh) | 2015-02-11 | 2015-02-11 | 一种门冬氨酸鸟氨酸晶型iv及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105985252B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440324A (zh) * | 2018-04-19 | 2018-08-24 | 成都倍特药业有限公司 | 一种门冬氨酸鸟氨酸及其结晶方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0920737A (ja) * | 1995-06-30 | 1997-01-21 | Nitto Chem Ind Co Ltd | クロルアセトアルデヒドまたはそのアセタールを原料とする生分解性キレート剤、l,l−エチレンジアミンジコハク酸の製造方法 |
CN101987094A (zh) * | 2009-08-07 | 2011-03-23 | 上海秀新臣邦医药科技有限公司 | 门冬氨酸鸟氨酸注射液及其制备方法 |
CN102827017A (zh) * | 2011-06-14 | 2012-12-19 | 上海励睿化学科技有限公司 | 一种复盐化合物晶型及其制备方法 |
-
2015
- 2015-02-11 CN CN201510071457.6A patent/CN105985252B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0920737A (ja) * | 1995-06-30 | 1997-01-21 | Nitto Chem Ind Co Ltd | クロルアセトアルデヒドまたはそのアセタールを原料とする生分解性キレート剤、l,l−エチレンジアミンジコハク酸の製造方法 |
CN101987094A (zh) * | 2009-08-07 | 2011-03-23 | 上海秀新臣邦医药科技有限公司 | 门冬氨酸鸟氨酸注射液及其制备方法 |
CN102827017A (zh) * | 2011-06-14 | 2012-12-19 | 上海励睿化学科技有限公司 | 一种复盐化合物晶型及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440324A (zh) * | 2018-04-19 | 2018-08-24 | 成都倍特药业有限公司 | 一种门冬氨酸鸟氨酸及其结晶方法 |
CN108440324B (zh) * | 2018-04-19 | 2021-04-20 | 成都倍特药业股份有限公司 | 一种门冬氨酸鸟氨酸及其结晶方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105985252B (zh) | 2020-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9126928B2 (en) | 4-hydroxy-2-oxo-1-pyrrolidineacetamide racemate crystal form I and preparation method therefor | |
DK2413924T3 (en) | L-ORNITHINPHENYL ACETATE AND PROCEDURES FOR PREPARING IT | |
US10364244B2 (en) | Crystal form of pyrroloquinoline quinone sodium salt and preparation method and use thereof | |
AU2015221466B2 (en) | L-ornithine phenyl acetate and methods of making thereof | |
CN112125899B (zh) | 吡咯并喹啉醌二钠盐结晶、其制备方法及包含其的组合物 | |
CN106995397B (zh) | R-氨磺必利药用盐、制备方法、晶型及其用途 | |
CN107814802A (zh) | 一种制备枸橼酸托法替尼药用晶型的新方法 | |
TWI697498B (zh) | 一種苯並二氮雜䓬衍生物的氫溴酸鹽及其製備方法和用途 | |
CN103724374A (zh) | 一种苯磷硫胺化合物及制备方法及其含有该化合物的药物组合物 | |
CN104447541A (zh) | 博舒替尼化合物 | |
TW201925190A (zh) | 嘧啶基胺基─吡唑化合物之多晶型物及固體形式及製備方法 | |
CN112375093A (zh) | 一种克立硼罗晶型化合物及其制备方法 | |
CN102060844B (zh) | 一种法舒地尔的晶型ⅳ及其制备方法和用途 | |
CN105985252A (zh) | 一种门冬氨酸鸟氨酸晶型iv及其制备方法 | |
JP6965274B2 (ja) | ナトリウム−グルコース結合輸送体阻害剤のアミン溶媒和物、その調製方法およびその適用 | |
CN102746227B (zh) | 一种磷酸二甲啡烷晶型ⅱ及制备方法和药物组合物 | |
EP3004103A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5 d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
CN111670191B (zh) | 吡啶酮衍生物的晶型及制备方法和应用 | |
CN104768927B (zh) | (3s,3s’)‑4,4’‑二硫烷二基双(3‑氨基丁烷‑1‑磺酸)合l‑赖氨酸的新的结晶相 | |
CN114105888B (zh) | 丙基硫氧嘧啶与具有抗氧化活性的营养素小分子的共晶及其制备方法 | |
EP3004104A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
CN109942487A (zh) | 一种吡啶类化合物及其制备方法、用途 | |
CN115403538B (zh) | 一种依帕司他晶型及其制备方法和应用 | |
EP3342778B1 (en) | Crystal form of fludarabine phosphat, preparation method therefor, and application thereof | |
CN109384739B (zh) | 一种可比司他新晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230331 Address after: 430223 Miao Shan District, East Lake New Technology Development Zone, Hubei, Wuhan Patentee after: WUHAN QR PHARMACEUTICALS Co.,Ltd. Patentee after: WUHAN ZHONGYOU PHARMACEUTICAL Co.,Ltd. Address before: 201206 5th floor, block a, building 1, 3333 Shenjiang Road, Pudong New Area, Shanghai Patentee before: SHANGHAI MEIYUE BIOTECH DEVELOPMENT Co.,Ltd. Patentee before: WUHAN QR PHARMACEUTICALS Co.,Ltd. Patentee before: WUHAN ZHONGYOU PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 430223 Miao Shan District, East Lake New Technology Development Zone, Hubei, Wuhan Patentee after: WUHAN QR PHARMACEUTICALS Co.,Ltd. Patentee after: Wuhan Ruisheng Pharmaceutical Co.,Ltd. Address before: 430223 Miao Shan District, East Lake New Technology Development Zone, Hubei, Wuhan Patentee before: WUHAN QR PHARMACEUTICALS Co.,Ltd. Patentee before: WUHAN ZHONGYOU PHARMACEUTICAL Co.,Ltd. |